Trial Profile

A Single-Arm, Open-Label, Phase I/II Study of Glasdegib for Sclerotic Chronic Graft-Vs-Host Disease

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 31 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glasdegib (Primary)
Indications Graft-versus-host disease; Sclerosis
Focus Adverse reactions

Most Recent Events

11 Sep 2023 Status changed from active, no longer recruiting to discontinued.
13 Dec 2022 Results from two clinical studies: NCT03415867 and NCT04111497 assessing safety and efficacy of glasdegib in adult patients with refractory scGVHD at data cutoff of 12-months presented at the 64th American Society of Hematology Annual Meeting and Exposition
13 Jun 2022 Planned End Date changed from 30 Jun 2024 to 1 Oct 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com